Alkeus Pharmaceuticals, Inc., a biopharmaceutical company based in Massachusetts, has named Dr. Seemi Khan as its Chief Medical Officer. Dr. Khan expressed anticipation about joining Alkeus, especially with the promising progress of Gildeuretinol (ALK-001) in treating Stargardt disease. Leonide Saad, the CEO, welcomed Dr. Khan, highlighting her success in bringing rare disease treatments to patients.
Dr. Khan, known for her executive accomplishments, aims to assemble a team to make a significant impact on individuals facing vision loss. Her commitment to medical innovation aligns with Alkeus’ mission. Previously, she served as Chief Medical Officer at Reata Pharmaceuticals, contributing to the approval and launch of the first Friedreich’s ataxia treatment.
With expertise in rare diseases, immunology, and rheumatology, Dr. Khan served in leadership roles at Mitsubishi Tanabe Pharma America, Quark Pharmaceuticals, Abbott, and AbbVie. She is a nephrologist and an assistant professor at Tufts University School of Medicine. Alkeus Pharmaceuticals, co-founded by Leonide Saad and Ilyas Washington, focuses on eye disease therapies, with Gildeuretinol (ALK-001) undergoing clinical trials for Stargardt disease and geographic atrophy.
